| Regenerative Medicine Press Releases + Feed Topics Locations Industries Dates
By Liveyon Liveyon provides high-quality, medical umbilical cord cells and growth factors for use in research studies for various degenerative diseases.
| By Blue Horizon International Brian Mehling, M.D. and Pavel Yufit, M.D., orthopedic surgeons with practices in New York and New Jersey, are scheduled to attend the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons in San Diego, CA from March 14-18, 2017 at the San...
| By Stemedica International Peer-reviewed Research Published in Nature's "Scientific Reports"
| By Blue Horizon International Brian Mehling, M.D., world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, and founder of Blue Horizon International (BHI), will be attending the 47th Annual World Economic Forum (WEF) in Davos from January 17-20, 2017.
| By Stemedica International Alexei Lukashev, PhD, General Manager, Awarded First Place in Russian Speaking Entrepreneur of the Year Competition
| By Stemedica International The Only Alzheimer's Disease Clinical Trial Using Stemedica's Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Continues Recruitment at UCI
| By ReGen Medical Dr. Steven Victor, CEO of ReGen Medical P.C., New York, stated "I am honored and pleased to now be certified by the Board of Regenerative Medicine after practicing this new and exciting specialty of medicine for the past 10 years." The American Academy...
| By Lipogems Lipogems, a global leader in regenerative medicine, has been named a recipient of Orthopedics This Week's "Best New Sports Medicine Technology of 2016" Award.
|  | By The Transplantation Society 26th International Congress of The Transplantation Society - August 18-23
|  | By The CHARMED Foundation The CHARMED Foundation is the first of its kind to support regenerative medicine research specific to pediatric illnesses and sports medicine
|  | By Blue Horizon International Brian Mehling, M.D., board-certified orthopedic surgeon and CMO of Blue Horizon International, presents data from “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at...
| By Stemedica International, SA Stemedica International, a subsidiary of Stemedica Cell Technologies, Inc.
| By AmnioChor Inc. AmnioChor Inc., an early stage biotech startup based on perinatal stem cell technology, is very pleased to announce that the Musculoskeletal Transplant Foundation of Edison NJ has agreed to invest in their seed round of development of the proprietary...
|  | By Blue Horizon International Dr. Mehling, a board-certified orthopedic surgeon and CMO of Blue Horizon International (BHI), will present “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at...
|
All Press Releases
By BioDivide Limited The new website offers visitors rich insights into the Company's lead stem cell product, StemPlan, and applied expertise of the therapeutic and biotechnology applications of stem cells.
| By Liveyon Liveyon provides high-quality, medical umbilical cord cells and growth factors for use in research studies for various degenerative diseases.
| By Acute Pain Therapies Recognized as a leader in pain management innovations with an expertise in regenerative medicine, ketamine for depression and peri and post-operative non-opioid pain management.
| By Top Knee Brace Reviews Osteoarthritis is the most common form of arthritis, affecting an estimated 54 million adults in the U.S. Many of those patients look to specialized knee braces to help deal with the pain.
| By Mary Ann Liebert, Inc., publishers Novel approaches to tissue engineering and regenerative medicine are first evaluated and optimized in animal models before making the leap to clinical testing in human subjects.
| By Coherent Market Insights Regenerative Medicine Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024
| By Blue Horizon International Brian Mehling, M.D. and Pavel Yufit, M.D., orthopedic surgeons with practices in New York and New Jersey, are scheduled to attend the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons in San Diego, CA from March 14-18, 2017 at the San...
| By Stemedica International Peer-reviewed Research Published in Nature's "Scientific Reports"
| By Blue Horizon International Brian Mehling, M.D., world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, and founder of Blue Horizon International (BHI), will be attending the 47th Annual World Economic Forum (WEF) in Davos from January 17-20, 2017.
| By Stemedica International Alexei Lukashev, PhD, General Manager, Awarded First Place in Russian Speaking Entrepreneur of the Year Competition
| By Stemedica International The Only Alzheimer's Disease Clinical Trial Using Stemedica's Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Continues Recruitment at UCI
| By ReGen Medical Dr. Steven Victor, CEO of ReGen Medical P.C., New York, stated "I am honored and pleased to now be certified by the Board of Regenerative Medicine after practicing this new and exciting specialty of medicine for the past 10 years." The American Academy...
| By Lipogems Lipogems, a global leader in regenerative medicine, has been named a recipient of Orthopedics This Week's "Best New Sports Medicine Technology of 2016" Award.
| | By The Transplantation Society 26th International Congress of The Transplantation Society - August 18-23
| By charleston sports medicine Dr. Bright McConnell focuses on regenerative medicine and takes a minimally invasive approach to treatment of injuries at Charleston Sports Medicine. One treatment, Subchondroplasty, may prevent some from undergoing total knee replacement.
| By Visiongain A new report by visiongain predicts that the Translational Regenerative Medicine market will reach $12.1bn in 2020.
| | By The CHARMED Foundation The CHARMED Foundation is the first of its kind to support regenerative medicine research specific to pediatric illnesses and sports medicine
| By Charleston Sports Medicine At Charleston Sports Medicine, Bright McConnell, III, MD combines traditional orthopedics with cutting-edge techniques in regenerative medicine. www.charlestonsportsmed.com.
| | By Blue Horizon International Brian Mehling, M.D., board-certified orthopedic surgeon and CMO of Blue Horizon International, presents data from “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at...
| By Stemedica International, SA Stemedica International, a subsidiary of Stemedica Cell Technologies, Inc.
| By Shibuya Kogyo Co Ltd Patent and technical know-how licensing agreement between Yamaguchi University and Shibuya Kogyo, Co. Ltd. for advanced regenerative medicine treatment for liver disease.
| By Shibuya Kogyo Co Ltd Shibuya Announces Business Expansion in Regenerative Medicine Market
| By AmnioChor Inc. AmnioChor Inc., an early stage biotech startup based on perinatal stem cell technology, is very pleased to announce that the Musculoskeletal Transplant Foundation of Edison NJ has agreed to invest in their seed round of development of the proprietary...
| By Mary Ann Liebert Inc., publishers Rapid, large-scale screening to characterize the different subpopulations of multipotent cells that can be derived from fat tissue is an effective strategy to identify and select for specific cell types that would be advantageous for particular...
| | By Blue Horizon International Dr. Mehling, a board-certified orthopedic surgeon and CMO of Blue Horizon International (BHI), will present “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at...
| By Visiongain Who are the leading developers and producers of stem cells in 2015, and what are their outlooks? Visiongain’s new study explains A new report by visiongain predicts the world stem cell technology market will generate $13.8bn in 2019, with rapid sales...
|
Page: 1 Page updated every 10 minutes
| |
